Sign in
Not yet recruitingPhase 2

Substudy to Evaluate the Potential Treatment Effect of the ABBV-7066 (risankizumab/ABBV-701) Combination Compared to Each Respective Monotherapy in Subjects with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis

Key facts

Who runs it
AbbVie Deutschland GmbH & Co. KG
Where
Belgium9 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
13 people, planned
Starts
15 Dec 2026
Expected to end
10 Mar 2031
Type of study
Interventional
Record updated
17 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Crohn's Disease specific: Crohn's Disease Activity Index (CDAI) score of ≥ 220
  • Crohn's Disease specific: Confirmed diagnosis of CD at least 90 days prior to Baseline
  • Crohn's Disease specific: Endoscopic evidence of mucosal inflammation as documented by an Simple Endoscopic Score for Crohn's Disease (SES-CD) of ≥ 6 for ileocolonic or colonic disease or SES-CD of ≥ 4 for isolated ileal disease
  • Crohn's Disease specific: Demonstrated failure of 1 or more therapy for CD
  • Ulcerative Colitis specific: Confirmed diagnosis of UC at least 90 days prior to Baseline
  • Ulcerative Colitis specific: Active UC with a modified Mayo Score (mMS) of 5 to 9 points and endoscopic subscore (ESS) of 2 to 3
  • Ulcerative Colitis specific: Demonstrated failure of 1 or more therapy for UC

Who cannot take part

  • Participants with demonstrated intolerance to p19 IL-23 inhibitors (including risankizumab)
  • Participants treated with any investigational drug within 30 days or 5 halflives of the study treatments (whichever is longer) prior to the first dose of study treatment
  • Participants who received any ATs (biologic or small molecules) prior to first dose of study treatment within the protocol specified time frame
  • Participants with surgical bowel resection within the past 3 months prior to Baseline
  • Crohn's Disease specific: Participants with >3 prior bowel resections
  • Crohn's Disease specific: Participants with previous small bowel resection(s) of combined length >100 cm
  • Ulcerative Colitis specific: Participants with prior colectomy (total or subtotal)
  • Ulcerative Colitis specific: Participants with extent of disease limited to < 10 cm of rectum

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Substudy 2: To evaluate efficacy and safety of the ABBV-7066 (risankizumab/ABBV-701) combination compared to the respective monotherapy component in adult subjects with moderately to severely active CD or UC.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 2 Platform Basket Study Evaluating Advanced Therapies in Subjects with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis
Record updated
17 November 2026